New trial aims to match sepsis treatments to Patients' unique traits
NCT ID NCT06381661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving sepsis patients drugs tailored to their specific biological traits can improve survival and reduce the need for life support. It will enroll 2000 adults and children across multiple countries, using an adaptive platform to test several treatments at once. The goal is to move away from one-size-fits-all sepsis care toward more personalized medicine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tocilizumab, Baricitinib, Anakinra, Hydrocortisone
- What this could lead to
- If successful, this could show that matching sepsis treatments to individual patient traits improves survival and reduces time on life support.
- What could go wrong
- This is an early Phase 2 exploratory trial, so results may not confirm effectiveness. The complex adaptive design may also make it harder to draw clear conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- Can brain waves predict thinking problems after sepsis?
- Can tailored nutrition boost recovery in the ICU?
- Blood markers may foretell brain fog after sepsis
- A hidden clue in the fingertips: could a pulse oximeter reading forecast sepsis outcomes?